EGFR and lung carcinoma: Moreover, because AURKA can enhance the resistance of lung cancer to third-generation EGFR inhibitors [19], a dual effect of AURKA SNPs and EGFR mutations on the clinicopathological characteristics of LADC may occur, thus requiring evaluation.